Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

 
• By Ayisha Sharma

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.  

Emerging Company Profile: Iksuda Therapeutics
PermaLink Can Design ADCs That Are Insusceptible To De-Conjugation • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs